Prognostic Role of Serum Chloride Levels in Acute Decompensated Heart Failure  by Grodin, Justin L. et al.
J O U R N A L O F T H E AM E R I C A N C O L L E G E O F C A R D I O L O G Y VO L . 6 6 , N O . 6 , 2 0 1 5
ª 2 0 1 5 B Y T H E AM E R I C A N C O L L E G E O F C A R D I O L O G Y F O U N DA T I O N I S S N 0 7 3 5 - 1 0 9 7 / $ 3 6 . 0 0
P U B L I S H E D B Y E L S E V I E R I N C . h t t p : / / d x . d o i . o r g / 1 0 . 1 0 1 6 / j . j a c c . 2 0 1 5 . 0 6 . 0 0 7Prognostic Role of Serum Chloride Levels
in Acute Decompensated Heart Failure
Justin L. Grodin, MD,* Jennifer Simon, BA,y Rory Hachamovitch, MD,* Yuping Wu, PHD,z Gregory Jackson, MD,x
Meghana Halkar, MD,k Randall C. Starling, MD, MPH,* Jeffrey M. Testani, MD, MTR,y W.H. Wilson Tang, MD*{ABSTRACTFro
Ap
Cle
Ca
an
gra
Ins
pa
Lis
MaBACKGROUND Acute decompensated heart failure (ADHF) can be complicated by electrolyte abnormalities, but the
major focus has been concentrated on the clinical signiﬁcance of serum sodium levels.
OBJECTIVES This study sought to determine the prognostic signiﬁcance of serum chloride levels in relation to serum
sodium levels in patients with ADHF.
METHODS We reviewed 1,318 consecutive patients with chronic heart failure admitted for ADHF to the Cleveland Clinic
between July 2008 and December 2013. We also validated our ﬁndings in an independent ADHF cohort from the
University of Pennsylvania (n ¼ 876).
RESULTS Admission serum chloride levels during hospitalization for ADHF were independently and inversely associated
with long-term mortality (hazard ratio [HR] per unit change: 0.94; 95% conﬁdence interval [CI]: 0.92 to 0.95;
p < 0.001). After multivariable risk adjustment, admission chloride levels remained independently associated with
mortality (HR per unit change: 0.93; 95% CI: 0.90 to 0.97; p < 0.001) in contrast to admission sodium levels, which
were no longer signiﬁcant (p > 0.05). Results were similar in the validation cohort in unadjusted (HR per unit change for
mortality risk within 1 year: 0.93; 95% CI: 0.91 to 0.95; p < 0.001) and multivariable risk-adjusted analysis (HR per unit
change for mortality risk within 1 year: 0.95; 95% CI: 0.92 to 0.99; p ¼ 0.01).
CONCLUSIONS These observations in a contemporary advanced ADHF cohort suggest that serum chloride levels at
admission are independently and inversely associated with mortality. The prognostic value of serum sodium in ADHF was
diminished compared with chloride. (J Am Coll Cardiol 2015;66:659–66) © 2015 by the American College of Cardiology
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distal nephron, increasing free water absorption and
potentially reducing serum sodium and chloride levels
(1,2). These electrolyte perturbations may be exacer-
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ABBR EV I A T I ON S
AND ACRONYMS
ADHF = acute decompensated
heart failure
CI = conﬁdence interval
HF = heart failure
HR = hazard ratio
ICD = implantable
cardioverter-deﬁbrillator
LV = left ventricular
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660excessive decongestion therapy. Further-
more, lower serum chloride levels relative to
sodium levels may identify an electrolyte-
deplete acute decompensated HF (ADHF)
phenotype with different prognostic conse-
quences. This study aimed to determine the
independent and incremental long-term
prognostic impact of admission serum chlo-
ride levels after hospitalization for ADHF.
METHODSSTUDY POPULATION AND DATA SYNTHESIS. The Cleve-
land Clinic Institutional Review Board approved this
study. We identiﬁed 1,318 unique, consecutive pa-
tients admitted to the internal medicine or cardiology
inpatient services at the Cleveland Clinic between
July 28, 2008, and December 31, 2013, with a
discharge diagnosis of ADHF. We conﬁrmed the
discharge diagnosis by performing a search of the
International Classiﬁcation of Diseases-Ninth Revi-
sion codes for acute or chronic HF (428.x). To further
improve the speciﬁcity of selecting an established
chronic HF population, only patients with a docu-
mented prior cardiac implantable electronic device
(implantable cardioverter-deﬁbrillator [ICD] or car-
diac resynchronization therapy) were retained in the
registry. The presence of an ICD or cardiac resynch-
ronization therapy device was conﬁrmed if there
was a prior medical encounter caused by such a de-
vice (V45.02), radiological examination suggesting
the presence of an ICD or cardiac resynchronization
therapy, electronic analysis of an ICD (including
interrogation, evaluation of generator status or pro-
gramming parameters, electrocardiographic analysis,
or a wearable cardioverter-deﬁbrillator system), or
procedure in which there was a prior insertion or
repositioning of an electrode lead for a single-
or dual-chamber pacing ICD and insertion of a pulse
generator.
Patients were excluded if they were not given a
loop diuretic during admission, did not have an active
medication list, were <18 years of age, had prior heart
transplantation or mechanical circulatory assist de-
vice, or were on chronic dialysis therapy. Only the
ﬁrst admission for a patient was included in the
cohort if they were subsequently readmitted. Long-
term all-cause mortality was determined from the
electronic medical record and validated, if possible,
by the Social Security Death Index. All patients were
followed until December 31, 2013.
VALIDATION COHORT. Charts of consecutive admis-
sions to noninterventional cardiology or internal
medicine services at the Hospital of the University ofPennsylvania from 2004 to 2009 were reviewed. The
assembly and characteristics of patients in this cohort
have been previously described (14,15). Brieﬂy, in-
clusion required a primary discharge diagnosis of
congestive HF, a hospital admission length between
3 and 14 days, and a B-type natriuretic peptide level
>100 pg/ml within 24 h of admission. Patients on
renal-replacement therapy were excluded from anal-
ysis, as were patients without documentation of
speciﬁc HF etiology, available blood chemistry values
at admission, or baseline medication use information.
As in the derivation cohort, in the case of multiple
admissions for a single patient, only the ﬁrst admis-
sion was included. Clinical, demographic, imaging,
and laboratory data, and documented primary and
secondary diagnoses were reviewed from the elec-
tronic medical record. Admission chloride was
deﬁned as the level on ﬁrst blood draw on presenta-
tion; discharge chloride was determined using the
blood draw on the day of discharge. All patients were
followed until June 30, 2012, and death was veriﬁed
by the Social Security Death Index.
STATISTICAL METHODS. Continuous variables were
expressed as median (interquartile range) and cate-
gorical variables were expressed as percent. The
Jonkheere-Terpstra and Cuzick methods were used to
test trend across tertiles of admission chloride levels
for continuous and categorical variables, respectively
(16). Spearman correlation coefﬁcients (r) were used
to show correlations between continuous variables.
Survival analyses were completed via the Kaplan-
Meier method and log-rank test to compare survival
curves across admission chloride tertiles. Cox pro-
portional hazards models were used to examine the
association between chloride levels and time to all-
cause mortality after adjusting for potential con-
founders. Hazard ratios (HRs) and 95% conﬁdence
intervals (CIs) for all-cause mortality were determined
for all covariates. Proportional hazard assumption vi-
olations were estimated by generalized linear regres-
sion of scaled Schoenfeld residuals on time. For
proportional hazard violations (p < 0.1), “within-
stratum” estimates were provided for models strati-
ﬁed by categorical variables, and Heaviside functions
were used to determine the time-dependency of risk
for continuous variables. The model covariates were
selected a priori (based on previous prognostic reports
in patients with HF and clinical experience) either
because of their prognostic relevance or their poten-
tial to confound the chloride-risk relationship. These
included admission sodium, blood urea nitrogen,
length of stay (days), age (years), ischemic cardiomy-
opathy, beta-blocker use, renin-angiotensin system
J A C C V O L . 6 6 , N O . 6 , 2 0 1 5 Grodin et al.
A U G U S T 1 1 , 2 0 1 5 : 6 5 9 – 6 6 Chloride in Acute Decompensated Heart Failure
661inhibitor use, and mineralocorticoid antagonist
use (17,18). The discrimination (C statistic) of the
impact of chloride levels on mortality was deter-
mined as previously described (19). Category-free
net-reclassiﬁcation indexes and integrated discrimi-
nation improvement were calculated to further
clarify the incremental prognostic value of chloride
(20). Double-sided p values <0.05 were considered
statistically signiﬁcant. Statistical analyses were
performed using Stata version 13.1 software (Stata-
Corp LP, College Station, Texas).
RESULTS
BASELINE CHARACTERISTICS. Baseline characteris-
tics for the Cleveland Clinic and University of Penn-
sylvania cohorts are shown in Tables 1 and 2,
respectively. For the Cleveland Clinic cohort, admis-
sion chloride levels were normally distributed, with
median and mean admission chloride being 101 (in-
terquartile range: 97 to 104) mEq/l and 100  6 mEq/l,
respectively. As expected, admission chloride levels
were directly correlated to admission sodium levels
(r ¼ 0.61; p < 0.001) and negatively correlated to
admission bicarbonate levels (r ¼ 0.39; p < 0.001).
Higher chloride levels were positively associated
with increasing LV ejection fraction, beta-blocker
and renin-angiotensin system–blocker use, and
renal dysfunction, but negatively associated with
markers of neurohormonal activation (blood urea
nitrogen and N-terminal pro–B-type natriureticTABLE 1 Baseline Characteristics of the Cleveland Clinic Cohort
Total (N ¼ 1,318) <99 (n ¼ 45
Age, yrs 68.7 (59.1 to 77.2) 67.9 (59.2 to 7
Male 70.0 71.9
Ischemic cardiomyopathy 34.8 33.6
LVEF, % (n ¼ 1,068) 27 (19 to 45) 25 (15 to 40)
SBP, mm Hg 118 (105 to 137) 111 (102 to 12
Beta-blocker 84.9 80.3
RAS blocker 59.2 52.2
MRA 36.3 43.4
Sodium, mEq/l 137 (135 to 140) 134 (131 to 13
Bicarbonate, mEq/l 25 (22 to 27) 27 (24 to 30
BUN, mg/dl 27 (19 to 40) 31 (22 to 47)
Creatinine, mg/dl 1.28 (0.99 to 1.69) 1.33 (1.04 to 1
NT-proBNP, pg/ml (n ¼ 481) 4,817 (2,415 to 9,536) 5,793 (3,133 to
Hemoglobin, g/dl 11.6 (10.1 to 13.1) 11.6 (10.2 to 1
Total bilirubin, mg/dl 0.8 (0.5 to 1.3) 1.0 (0.6 to 1.
Length of stay, days 8.7 (5.0 to 16.7) 9.7 (5.5 to 19
DWeight during admission, kg -2.5 (-6.0 to 0.1) -2.9 (-6.8 to 0
Values are median (interquartile range) or %. *p value for the Jonckheere-Terstra or Cu
BUN ¼ blood urea nitrogen; LVEF ¼ left ventricular ejection fraction; MRA ¼ min
RAS ¼ renin-angiotensin system; SBP ¼ systolic blood pressure.peptide) and indicators of end-organ function (he-
moglobin and bilirubin). They were also inversely
related to length of stay in the hospital and net weight
change during admission.
CHLORIDE LEVELS AND ALL-CAUSE MORTALITY. The
Cleveland Clinic cohort of 1,318 patients had 2,261
person-years of follow-up for all-cause mortality.
There were 359 deaths over a median follow-up
time of 1.47 (interquartile range: 0.51 to 2.68) years.
Kaplan-Meier survival estimates were different
across tertiles of admission chloride level (log-rank
p < 0.001 for all) (Central Illustration). There were
164, 127, and 68 deaths for tertiles 1 to 3, respectively.
Tertile 1 had a higher death incidence rate of
0.22 death/person-years compared with tertiles
2 and 3 with 0.14 and 0.10 death/person-years,
respectively.
Per the univariable and multivariable proportional
hazards models (Table 3), admission chloride levels
were inversely associated with mortality (p < 0.001).
Every unit increase in chloride was associated with an
w6% relative improvement in survival (HR per unit
change: 0.94; 95% CI: 0.92 to 0.95; p < 0.001).
Although admission sodium levels were also
inversely associated with mortality (HR per unit
change: 0.95; 95% CI: 0.93 to 0.97; p < 0.001),
admission chloride levels showed greater discrimi-
nation for mortality (C statistic: 0.60; 95% CI: 0.57 to
0.64) than admission sodium levels (C statistic: 0.56;
95% CI: 0.53 to 0.59; p < 0.001). There was noAdmission Chloride (mEq/l)
p Value*6) 99 to 103 (n ¼ 497) >103 (n ¼ 365)
6.2) 68.4 (58.7 to 77.3) 69.5 (60.1 to 78.2) 0.09
69.8 67.7 0.19
38.2 31.5 0.64
25 (20 to 45) 34 (20 to 50) <0.001
8) 120 (105 to 137) 127 (113 to 144) <0.001
88.3 86.0 0.01
62.2 63.8 <0.001
36.0 28.0 <0.001
7) 138 (136 to 149) 138 (138 to 142) <0.001
) 25 (23 to 27) 23 (21 to 25) <0.001
27 (19 to 38) 25 (18 to 34) <0.001
.77) 1.29 (0.96 to 1.71) 1.20 (0.98 to 1.60) 0.004
10,418) 4,268 (2,180 to 9,175) 4,684 (2,428 to 8,644) 0.044
3.2) 11.7 (10.2 to 13.2) 11.3 (9.7 to 12.7) 0.003
5) 0.8 (0.5 to 1.3) 0.8 (0.5 to 1.1) <0.001
.4) 9.0 (4.9 to 17.8) 7.9 (4.9 to 14.1) <0.001
.0) -2.8 (-6.3 to 0.0) -1.5 (-4.4 to 0.3) <0.001
zick tests of trend.
eralocorticoid antagonist; NT-proBNP ¼ N-terminal pro–B-type natriuretic peptide;
TABLE 2 Baseline Characteristics of the University of Pennsylvania Cohort
Total (N ¼ 876)
Admission Chloride (mEq/l)
p Value*<101 (n ¼ 253) 101 to 104 (n ¼ 262) >104 (n ¼ 361)
Age, yrs 62.9 (51.4 to 74.3) 64.9 (53.8 to 74.8) 59.2 (48.3 to 72.7) 64.5 (52.3 to 75.6) 0.67
Male 54.3 60.1 59.2 46.8 0.001
Ischemic cardiomyopathy 24.2 33.6 16.8 23.0 0.01
LVEF, % 27.5 (15 to 47.5) 27.5 (15 to 50) 25 (15 to 45) 30 (15 to 47.5) 0.48
SBP, mm Hg 135 (115 to 158) 120 (102 to 143) 138 (118 to 161) 145 (126 to 166) <0.001
Beta-blocker 67.4 71.5 66.4 65.1 0.10
RAS blocker 61.2 60.9 63.7 59.6 0.67
MRA 15.1 22.5 14.1 10.5 <0.001
Sodium, mEq/l 139 (137 to 141) 136 (133 to 139) 139 (137 to 141) 141 (139 to 142) <0.001
Bicarbonate, mEq/l 25 (23 to 28) 28 (25 to 31) 26 (24 to 28) 24 (21 to 26) <0.001
BUN, mg/dl 22 (15 to 34) 30 (18 to 48) 20.5 (15 to 27) 21 (14 to 33) <0.001
Creatinine, mg/dl 1.3 (1.0 to 1.7) 1.40 (1.0 to 1.8) 1.2 (1.0 to 1.5) 1.3 (1.0 to 1.7) 0.19
BNP, pg/ml 1,314 (673 to 2,435) 1,372 (715 to 2,845) 1,241 (649 to 2,113) 1,319 (671 to 2,389) 0.86
Hemoglobin, g/dl 12.3 (10.7 to 13.6) 12.2 (10.6 to 13.7) 12.6 (11.0 to 13.9) 12.1 (10.6 to 13.5) 0.44
Total bilirubin, mg/dl 0.8 (0.5 to 1.4) 0.9 (0.6 to 1.7) 0.9 (0.5 to 1.4) 0.7 (0.4 to 1.0) <0.001
Length of stay, days 5 (4 to 8) 6 (4 to 9) 5 (4 to 8) 5 (4 to 7) <0.001
DWeight during admission, kg -3.1 (-5.9 to 0.8) -2.6 (-5.9 to 0.7) -3.2 (-6.4 to 0.9) -3.4 (-5.4 to 0.7) 0.55
Values are median (interquartile range) or %. *p value for the Jonckheere-Terstra or Cuzick tests of trend.
BNP ¼ B-type natriuretic peptide; other abbreviations as in Table 1.
CENTRAL ILLUSTRATION Chloride in Acute Decompensated Heart Failure: Survival Estimates by Admission Chloride Levels
Grodin, J.L. et al. J Am Coll Cardiol. 2015; 66(6):659–66.
For the Cleveland Clinic cohort, Kaplan-Meier survival estimates signiﬁcantly differed across tertiles of admission chloride level (log-rank p < 0.001), with
worse survival for lower admission chloride levels.
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TABLE 3 Univariable and Multivariable Cox Proportional Hazards Models for Mortality
Univariable Multivariable
HR 95% CI p Value HR 95% CI p Value
Cleveland Clinic Cohort
Chloride, mEq/l 0.94 0.92–0.95 <0.001 0.93* 0.90–0.97 <0.001
Sodium, mEq/l 0.95 0.93–0.97 <0.001
Log BUN, mg/dl 2.59 2.14–3.14 <0.001 2.00* 1.61–2.48 <0.001
Ischemic cardiomyopathy 1.36 1.10–1.68 0.004
Beta-blocker 0.74 0.56–0.97 0.028
RAS blocker 0.77 0.63–0.95 0.015
SBP, mm Hg 0.991 0.986–0.995 <0.001 0.993* 0.988–0.998 0.01
Age, yrs 1.02 1.01–1.03 <0.001 1.02* 1.01–1.03 <0.001
Bicarbonate, mEq/l 1.03 1.01–1.06 0.011
Length of stay, days 1.002 0.999–1.005 0.14
University of Pennsylvania Cohort
Chloride, mEq/l, #1 yr 0.93† 0.91–0.95 <00.001 0.95† 0.92–0.99 0.01
Chloride, mEq/l, >1 yr 0.99† 0.97–1.02 0.56
Sodium, mEq/l 0.96 0.94–0.98 <0.001
Log BUN, mg/dl 2.13 1.83–2.48 <0.001 1.60 1.34–1.91 <0.001
Ischemic cardiomyopathy 1.48 1.21–1.81 <0.001
Beta-blocker 1.15 0.94–1.41 0.16
RAS blocker 0.96 0.79–1.15 0.63
MRA 1.14 0.88–1.47 0.33
SBP, mm Hg 0.994 0.991–0.997 <0.001 0.996 0.992–0.999 0.01
Age, yrs 1.032 1.026–1.039 <0.001 1.03 1.02–1.04 <0.001
Bicarbonate, mEq/l 1.01 0.99–1.03 0.337
Length of stay, days 1.05 1.02–1.08 0.001 1.03 1.00–1.07 0.04
*Within-stratum estimate stratiﬁed by MRA use. †HRs reported for both Heaviside functions in same model.
CI ¼ conﬁdence interval; HR ¼ hazard ratio; other abbreviations as in Table 1.
FIGURE 1 Survival Estimates Stratiﬁed by Admission
Hypochloremia and Hyponatremia
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Kaplan-Meier survival curve estimates classiﬁed by levels of chloride (< or$96 mEq/l) and
sodium (< or $134 mEq/l) on admission demonstrate that chloride levels may provide a
stronger prognosis role than sodium levels.
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663signiﬁcant interaction between admission chloride
and sodium levels for mortality (p ¼ 0.19). Kaplan-
Meier survival estimates stratiﬁed by admission
hypochloremia (chloride <96 mEq/l) and hypona-
tremia (sodium <134 mEq/l) are shown in Figure 1,
which graphically illustrates that chloride levels may
have a stronger prognostic role than sodium levels.
After multivariable adjustment, admission chloride
levels remained independently inversely associated
with mortality (HR per unit change: 0.93; 95% CI: 0.90
to 0.97; p < 0.001) (Figure 2). Mortality risk increased
with decreasing chloride levels below w96 mEq/l
and did not signiﬁcantly differ at values >96 mEq/l.
There was no increase in the overall C statistic of the
multivariable model with the addition of chloride
(0.68 vs. 0.69; p ¼ 0.5). However, adding chloride to
the multivariable model did signiﬁcantly reclassify
risk (integrated discrimination improvement, 10%;
p < 0.001; category-free net-reclassiﬁcation indexes,
17.2%; p ¼ 0.006). With additional adjustment for
weight change and blood urea nitrogen/creatinine
ratio, admission chloride levels remained signiﬁcantly
associated with mortality (HR per unit change: 0.93;
95% CI: 0.90 to 0.97; p < 0.001).
However, after multivariable adjustment for
other variables including admission chloride levels,
admission sodium levels were not independently
associated with mortality (HR per unit change: 1.03;
95% CI: 0.99 to 1.07; p ¼ 0.18). Discharge chloride
level was signiﬁcant when substituted for admission
chloride level (discharge sodium level was sub-
stituted for admission sodium level) in the multivar-
iable model for mortality (HR per unit change: 0.94;
95% CI: 0.92 to 0.97; p < 0.001) and is graphically
depicted in Figure 3.
To validate our present ﬁndings, we turned to an
independent acute HF cohort from the University of
Pennsylvania with longer follow-up (Table 3). Admis-
sion chloride distribution was comparable with our
study cohort (median: 103 [100 to 106] mEq/l; mean:
103  6 mEq/l). Baseline characteristics of this valida-
tion cohort are presented in Table 2. Similar to the
Cleveland Clinic cohort, admission chloride levels
were directly correlated to admission sodium (r¼0.54;
p < 0.001) and negatively correlated to admission bi-
carbonate levels (r ¼ -0.49; p < 0.001). There were 453
deaths out of 876 patients with 3,038 person-years of
follow-up for all-cause mortality. In contrast to the
derivation cohort, admission chloride levels violated
the proportional hazards assumption (p > 0.1) and
were thus analyzed as a Heaviside function with time
stratiﬁed at 1 year. Admission chloride levels were
inversely associated with 1-year mortality in unad-
justed (HR per unit change: 0.93; 95% CI: 0.91 to 0.95;p < 0.001) and adjusted analysis (HR per unit change:
0.95; 95% CI: 0.92 to 0.99; p ¼ 0.01). Additionally, the
adjusted association with admission sodium levels
was not signiﬁcant (HR per unit change: 0.99; 95% CI:
FIGURE 2 Mortality Risk per Adjusted Admission
Chloride Levels
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A ﬁtted curve was generated from residual estimates according
to admission chloride level at the Cleveland Clinic after multi-
variable adjustment for sodium, length of stay, bicarbonate,
blood urea nitrogen, age, ischemic cardiomyopathy, and drug use
(beta-blocker, renin-angiotensin system blocker, and mineralo-
corticoid antagonist). CI ¼ conﬁdence interval.
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6640.96 to 1.03; p ¼ 0.58). Similar to the Cleveland Clinic
cohort, discharge chloride level was signiﬁcant when
substituted for admission chloride level (discharge
sodium level was substituted for admission sodium
level) to the multivariable model for mortality (HR per
unit change: 0.97; 95% CI: 0.95 to 0.99; p ¼ 0.01).
DISCUSSION
In 2 contemporary cohorts of patients predomi-
nantly with systolic dysfunction hospitalized forFIGURE 3 Mortality Risk per Adjusted Discharge
Chloride Levels
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A ﬁtted curve was generated from residual estimates according
to discharge chloride level at the Cleveland Clinic after multi-
variable adjustment for sodium, length of stay, bicarbonate,
blood urea nitrogen, age, ischemic cardiomyopathy, and drug use
(beta-blocker, renin-angiotensin system blocker, and mineralo-
corticoid antagonist). CI ¼ conﬁdence interval.ADHF and electrolyte measures, we report several
key ﬁndings that highlight prognostic implications
of serum chloride. First, serum chloride levels were
independently and inversely associated with mor-
tality after multivariable adjustment for other
prognostic factors including serum sodium concen-
tration. Second, serum chloride levels modestly
enhanced mortality prediction compared with so-
dium levels. Furthermore, serum sodium levels
were no longer associated with mortality when
serum chloride levels were added to the multivari-
able model. Finally, although modestly correlated,
serum chloride and serum sodium levels had no
signiﬁcant interaction for mortality prediction.
These ﬁndings highlight the prognostic implications
of serum chloride level in ADHF and suggest that it
provides stronger prognostic information than
serum sodium level. Further investigations into the
clinical relevance of hypochloremia in the setting of
acute HF are warranted.
The pathological role of chloride in HF is incom-
pletely understood, in part because chloride levels
have been rarely documented in clinical trials or
registries. Chloride accounts for approximately one-
third of the tonicity and two-thirds of all negative
charges in the plasma (21). Dietary sodium chloride
is the main source of chloride in the body and its
removal is facilitated by gastric, sweat, and renal
excretion. Serum chloride levels may represent the
downstream effects of adversely prognostic mal-
adaptive neurohormonal, renal, and acid-base dis-
turbances in HF. Indeed, mechanisms that reduce
sodium levels can similarly lower chloride levels
(22). These include: 1) the pathological impairment
of free water excretion resulting from increased
nonosmotic release of arginine vasopressin (23),
which is typically increased in patients with symp-
tomatic HF (24,25); 2) the pleotropic effects of
excess angiotensin II on renal sodium and water
handling and neural thirst center activation (1); and
3) increased baroreceptor-mediated release of argi-
nine vasopressin (24). All of these mechanisms are
directly stimulated in HF (26). As a result, lower
chloride levels may be dilutional in nature. Yet they
may also represent a state of electrolyte depletion,
especially when chloride is lower relative to sodium,
which can occur in the setting of diuretic-induced
salt wasting as chloride is excreted in the urine
while bicarbonate is retained to maintain electro-
neutrality (27). Making this distinction may have
clinical implications when administering de-
congestive therapies for acute HF (28).
Both sodium and chloride levels were prog-
nostically similar in unadjusted, but not adjusted,
PERSPECTIVES
COMPETENCY IN PATIENT CARE AND PROCEDURAL
SKILLS: Like hyponatremia, hypochloremia in patients
hospitalized for ADHF is independently associated with
long-term mortality.
TRANSLATIONAL OUTLOOK: Additional clinical and
mechanistic studies are needed to investigate the pathophysi-
ology of electrolyte depletion in patients with ADHF and develop
therapeutic strategies that avoid the adverse consequences
associated with hypochloremia.
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665analyses, potentially suggesting a pathophysiolog-
ical difference in the 2 electrolytes. In the presence
of HF, the relative concentrations of sodium and
chloride in the plasma compartments can be low-
ered symmetrically or asymmetrically (29,30). This
may be related to the ability of the kidney to
excrete these electrolytes and modiﬁed by thera-
peutic measures (loop diuretics) and comorbid
conditions. Chloride is a buffer for cations, in-
cluding acid and sodium, and plays a major role in
the ability of the kidney to eliminate salt and water.
Therefore, in contrast to sodium, chloride has a
stronger prognostic role because it may play a
broader homeostatic role.
Our ﬁnding that lower chloride levels during
admission were associated with higher mortality of-
fers important insights into interpretation of elec-
trolytes in ADHF. Our ﬁndings suggest that although
sodium levels are important, more robust prognostic
information can be inferred from serum chloride
levels. Although low sodium has consistently been
shown to be a strong predictor of short- and long-
term morbidity and mortality in patients with both
systolic and diastolic HF (7,11,13,31,32), there was
little mention of the impact of chloride on the
interpretation of sodium levels in these analyses. As
our results suggest, these previous results may have
failed to take into account serum chloride levels.
Prior evidence for the prognostic role of chloride is
sparse, and there is no formalized deﬁnition of
hypochloremia in HF. Our observations highlight the
need to focus on better understanding of chloride
homeostasis and preserving it as a potential thera-
peutic consideration, particularly in the setting
of ADHF with extensive use of loop diuretics
that primarily inhibit the sodium-potassium-chloride
cotransporter leading to inevitable and excessive
chloride wasting.
STUDY LIMITATIONS. Our results must be inter-
preted in the context of several limitations in our
study design. We cannot exclude the presence of
selection bias for those undergoing evaluation and
treatment for ADHF at 2 tertiary care centers. How-
ever, the external validity of these ﬁndings is st-
rengthened with the addition of the validation
cohort. These patients largely had systolic dysfunc-
tion with questionable generalizability to an ADHF
population with preserved LV systolic function. Yet
this also afforded an opportunity for a diversity of
pathology in a contemporary cohort recorded by a
modern electronic medical record to be retrieved in
a very efﬁcient manner. Our analysis also displayed
a unique way of identifying patients presentingwith ADHF and established HF based on the history
of an ICD. Data were lacking regarding patient-level
decision making and resulting medication changes
and the impact they would have on changing chlo-
ride levels and prognosis. Similarly, the impact of
chloride levels on HF rehospitalizations could not be
determined. There was only a minority of patients
with serum chloride levels >107 mEq/l, and this
analysis was underpowered to determine increased
risk caused by hyperchloremia. To our knowledge,
however, therapies that increase serum chloride
concentrations, such as hypertonic saline, are rarely
used in ADHF populations, but the potential impact
of potassium supplementation with potassium ch-
loride is unclear. Nevertheless, this large, well-
powered ADHF cohort confers a new perspective
on serum chloride levels and their impact on
prognosis.
CONCLUSIONS
Serum chloride levels measured during hospitaliza-
tion for ADHF are independently and inversely asso-
ciated with long-term mortality. This association was
independent of, and added incremental prognostic
information to, serum sodium levels. These ﬁndings
highlight the clinical signiﬁcance of chloride, a rou-
tinely measured electrolyte, in long-term prognosti-
cation for ADHF.
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